Omniscient announced 510(k) clearance from the U.S. Food and Drug Administration for a new workflow within the Quicktome® platform: Quicktome Deep Br...
Leveragen, Inc., a Boston-based biotechnology company advancing in vivo antibody discovery, today announced the grant of Australian Patent No. 2022271276...
Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for s...
Telix Pharmaceuticals Limited announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET imaging agent...
Novonesis has signed an agreement with the intent to acquire MicroBioGen, an Australian biotechnology company with leading scientific expertise in yeast ...
Australian medtech investor Bioshore Ventures and US neurotechnology investor Jumpspace Ventures join Wellumio's oversubscribed pre-Series A round in the f...
BW-41012 represents the eighth clinical candidate from Argo's innovative RNAi pipeline, and is being evaluated for the prevention of thromboembolic disea...
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property c...
Anivive converts Laverdia-CA1 to full FDA approval First FDA-approved product to validate Anivive's AI-enabled development model — from drug rep...
LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”) announced an exclusive license and commercialization ...
Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pac...
IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities obser...
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced so...
Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), is pleased to announ...
© 2026 Biopharma Boardroom. All Rights Reserved.
